Beth Marsh is stepping into the role of Neurotech Pharmaceuticals’ chief commercial officer (CCO) beginning April 28. Marsh will lead the organization, particularly as it prepares for the US launch of ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida. Retina World Congress 2025 will take place May ...

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for broadening the dosing schedule to include every 4-week dosing across approved ...

Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida. Durga Borkar, MD, MMCi, spoke with Modern Retina ...

Atsena Therapeutics announced in a press release that the FDA granted its gene therapy product candidate, ATSN-201, the regenerative medicine advanced therapy (RMAT) designation to treat X-linked ...